Sangamo Biosciences reported $131.9M in Current Liabilities for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Acceleron Pharma XLRN:US $ 57.37M 2.11M
Alnylam Pharmaceuticals ALNY:US $ 610.66M 56.01M
Amgen AMGN:US $ 14842M 257M
Avrobio Inc AVRO:US $ 22.79M 5.84M
Bayer BAYN:GR € 28727M 801M
Biogen BIIB:US $ 4211.6M 864.4M
Biomarin Pharmaceutical BMRN:US $ 514.9M 71.55M
Bluebird Bio BLUE:US $ 266.56M 18.79M
Gilead Sciences GILD:US $ 10245M 31M
GlaxoSmithKline GSK:LN 22417M 1030M
IONIS PHARMACEUT IONS:US $ 218M 75.82M
Karyopharm Therapeutics KPTI:US $ 68.87M 10.74M
Novartis NOVN:VX SF 29880M 247M
Omeros OMER:US $ 42.82M 4.88M
Sangamo Biosciences SGMO:US $ 131.9M 5.04M
Sarepta Therapeutics SRPT:US $ 373.44M 51.58M
Ultragenyx Pharmaceutical RARE:US $ 135.93M 8.87M
Vertex Pharmaceuticals VRTX:US $ 1914.26M 77.82M
Ziopharm Oncology ZIOP:US $ 28.17M 14.58M